China Sxt Pharmaceuticals Stock Cash Per Share
| SXTC Stock | USD 0.40 0.01 2.44% |
China SXT Pharmaceuticals fundamentals help investors to digest information that contributes to China SXT's financial success or failures. It also enables traders to predict the movement of China Stock. The fundamental analysis module provides a way to measure China SXT's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to China SXT stock.
| Last Reported | Projected for Next Year | ||
| Cash Per Share | 13.92 | 13.22 |
China | Cash Per Share |
China SXT Pharmaceuticals Company Cash Per Share Analysis
China SXT's Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current China SXT Cash Per Share | 5.78 X |
Most of China SXT's fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, China SXT Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
China Cash Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for China SXT is extremely important. It helps to project a fair market value of China Stock properly, considering its historical fundamentals such as Cash Per Share. Since China SXT's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of China SXT's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of China SXT's interrelated accounts and indicators.
Click cells to compare fundamentals
China Cash Per Share Historical Pattern
Today, most investors in China SXT Stock are looking for potential investment opportunities by analyzing not only static indicators but also various China SXT's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's cash per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of China SXT cash per share as a starting point in their analysis.
China SXT Cash Per Share |
| Timeline |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
China Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
In accordance with the recently published financial statements, China SXT Pharmaceuticals has a Cash Per Share of 5.78 times. This is 32.87% higher than that of the Personal Care Products sector and significantly higher than that of the Consumer Staples industry. The cash per share for all United States stocks is 15.37% lower than that of the firm.
China Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses China SXT's direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of China SXT could also be used in its relative valuation, which is a method of valuing China SXT by comparing valuation metrics of similar companies.China SXT is currently under evaluation in cash per share category among its peers.
China Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.0497 | ||||
| Profit Margin | (1.61) % | ||||
| Operating Margin | 7.34 % | ||||
| Current Valuation | (7.78 M) | ||||
| Shares Outstanding | 4.06 M | ||||
| Shares Owned By Insiders | 16.94 % | ||||
| Shares Owned By Institutions | 1.34 % | ||||
| Number Of Shares Shorted | 66.96 K | ||||
| Price To Earning | 5.73 X | ||||
| Price To Book | 0.12 X | ||||
| Price To Sales | 0.84 X | ||||
| Revenue | 1.93 M | ||||
| Gross Profit | 1.25 M | ||||
| EBITDA | (2.35 M) | ||||
| Net Income | (3.1 M) | ||||
| Cash And Equivalents | 15.52 M | ||||
| Cash Per Share | 5.78 X | ||||
| Total Debt | 2.65 M | ||||
| Debt To Equity | 0.68 % | ||||
| Current Ratio | 1.31 X | ||||
| Book Value Per Share | 6.28 X | ||||
| Cash Flow From Operations | (1.93 M) | ||||
| Short Ratio | 0.22 X | ||||
| Earnings Per Share | (3.57) X | ||||
| Number Of Employees | 75 | ||||
| Beta | 1.16 | ||||
| Market Capitalization | 1.63 M | ||||
| Total Asset | 23.13 M | ||||
| Retained Earnings | (24.71 M) | ||||
| Working Capital | 5.33 M | ||||
| Net Asset | 23.13 M |
About China SXT Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze China SXT Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of China SXT using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of China SXT Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether China SXT Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of China SXT's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of China Sxt Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on China Sxt Pharmaceuticals Stock:Check out China SXT Piotroski F Score and China SXT Altman Z Score analysis. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Personal Care Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of China SXT. If investors know China will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about China SXT listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.426 | Earnings Share (3.57) | Revenue Per Share 2.223 | Quarterly Revenue Growth 0.295 | Return On Assets (0.05) |
The market value of China SXT Pharmaceuticals is measured differently than its book value, which is the value of China that is recorded on the company's balance sheet. Investors also form their own opinion of China SXT's value that differs from its market value or its book value, called intrinsic value, which is China SXT's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because China SXT's market value can be influenced by many factors that don't directly affect China SXT's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between China SXT's value and its price as these two are different measures arrived at by different means. Investors typically determine if China SXT is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, China SXT's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.